A polypeptide for enhancing porcine epidemic diarrhea virus replication and its application

The transmembrane peptide R58-WT, designed by targeting arginine at position 58 of the PEDV nucleocapsid N protein, solved the problem of low PEDV replication efficiency, enabling efficient virus rescue and preparation of vaccine candidate strains.

CN119080952BActive Publication Date: 2026-11-17ZHEJIANG UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411440195.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2026-11-17
Estimated Expiration
2044-10-15

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively enhance the replication of porcine epidemic diarrhea virus (PEDV), especially in the rescue of attenuated strains, which suffer from low virulence at lower passages, poor cell adaptability, and difficulty in passage, thus failing to meet the needs of large-scale experiments.

Method used

A transmembrane peptide targeting the PEDV replication stage was designed. The R58-WT peptide was synthesized using arginine at position 58 of the PEDV nucleocapsid N protein as the target. PEDV replication was promoted by pre-incubating cells and adding the peptide.

Benefits of technology

It significantly enhances the replication efficiency of PEDV, solves the problems of poor cell adaptability and difficult passage of attenuated strains, and provides a preparation method for virus isolation and attenuated vaccine candidate strains.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080952B_ABST
    Figure CN119080952B_ABST
Patent Text Reader

Abstract

This invention relates to bioengineering technology and aims to provide a polypeptide for enhancing porcine epidemic diarrhea virus (PEDV) replication and its application. This polypeptide is a transmembrane polypeptide targeting the PEDV replication stage, with arginine residue 58 in the nucleocapsid N protein sequence of PEDV as the target site; the polypeptide is named R58-WT polypeptide, and its amino acid sequence is shown in SEQ ID NO:1. This invention utilizes a key site in the N-terminal region of the PEDV N protein that affects viral replication as a novel target. This polypeptide showed a significant promoting effect in PEDV infection model validation experiments in IPEC-J2, Vero, and ST cells, perfectly solving the problems of weak virulence, poor cell adaptability, and difficulty in passage in the rescue of attenuated PEDV strains.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of bioengineering technology, specifically relating to a polypeptide for enhancing the replication of porcine epidemic diarrhea virus and its applications. Background Technology

[0002] Porcine epidemic diarrhea (PED) is an acute, highly contagious intestinal disease that causes vomiting, dehydration, and fatal watery diarrhea in piglets. Porcine epidemic diarrhea virus (PEDV), the causative agent of PED, belongs to the genus *A* coronaviruses in the family Coronaviridae. It is a single-stranded, positive-sense RNA virus enveloped in an envelope, spherical in shape with a diameter of approximately 90-190 nm. The envelope has petal-like projections that are widely spaced, regularly arranged, and crown-like. Its genome is approximately 28 kb in length, including a 5'-UTR (non-coding region with a 5' cap), a 3'-UTR (non-coding region with a 3'-A tail), and seven open reading frames (ORFs). The ORFs encode four structural proteins: spike (S) protein, envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein; one accessory protein (ORF3); and 16 non-structural proteins (Nsp 1-16).

[0003] The PEDV N protein has been reported to participate in viral replication and transcription, encapsulate the viral RNA genome, dynamically correlate with viral RNA replication sites, and play a role in protecting the viral genome and mediating genome transfer to budding sites. Furthermore, PEDV N can inhibit IFN-β expression, mediating viral immune escape through two mechanisms: disrupting the RIG-I / MDA5 cascade; and blocking the interaction between TBK1 and IRF3. Research on the PEDV N protein helps to elucidate the patterns of viral infection and transmission, and is of great significance for developing new epidemic prevention measures.

[0004] In the research on PEDV, a large number of complex tests and verifications are needed to assess the virus’s infection effects under different conditions. Therefore, providing a sufficient amount of virus for experiments is a prerequisite.

[0005] Isolation of PEDV has long been considered the "gold standard" for the clinical diagnosis of PED. Researchers typically isolate the virus by mixing fecal samples and diseased small intestine samples from infected pigs with phosphate-buffered saline (PBFS), followed by freeze-thaw centrifugation. The supernatant is then used to infect Vero cells in vitro, and after continuous passage and propagation, the clinical PEDV strain is obtained. However, this method is limited by PEDV's weak environmental resistance, poor cellular adaptability, trypsin dependence, and weak intercellular transmissibility.

[0006] PEDV live attenuated vaccines are widely studied in vaccine development due to their high immunogenicity. Currently, researchers mainly use two methods in the preparation of attenuated vaccines: one is to isolate the virus and continuously passage it in vitro to achieve higher viral titers, lower pathogenicity, and higher immunogenicity. For example, the live attenuated vaccine developed from the 28th generation cell culture of PEDV CV777 strain can provide more than 80% protection for immunized piglets; the other is based on research on PEDV virulence factors and immune-related epitopes, using efficient reverse genetics technology to artificially modify and screen the viral genome to obtain safer and more effective PEDV live attenuated vaccine candidate strains.

[0007] However, in the process of rescuing attenuated PEDV strains, the existing methods and research results mentioned above all suffer from problems such as weak virulence at lower passages, poor cell adaptability, and difficulty in passage, which cannot meet the needs of large-scale experiments for PEDV virus in practical applications. Therefore, it is necessary to propose new solutions. Summary of the Invention

[0008] The technical problem to be solved by the present invention is to overcome the shortcomings of the prior art and provide a polypeptide for enhancing the replication of porcine epidemic diarrhea virus and its application.

[0009] To solve the technical problem, the solution of the present invention is:

[0010] A polypeptide for enhancing porcine epidemic diarrhea virus replication is provided. This polypeptide is a membrane-penetrating polypeptide that targets the replication phase of PEDV and uses arginine at position 58 of the nucleocapsid N protein sequence of PEDV as the target site. The polypeptide is named R58-WT polypeptide, and its amino acid sequence is shown in SEQ ID NO:1.

[0011] As a preferred embodiment of the present invention, the N-terminus of the polypeptide is modified with a membrane-penetrating peptide, wherein the membrane-penetrating peptide is a CCP, and its sequence is shown in SEQ ID NO:2.

[0012] The present invention further provides a method for promoting PEDV-N protein expression using the aforementioned polypeptide, which involves pre-incubating IPEC-J2, Vero, or ST cells with the polypeptide, adding the same amount of polypeptide as during pre-incubation after PEDV infection, lysing the cells, harvesting the sample, and detecting the expression of PEDV-N protein in the cells.

[0013] As a preferred embodiment of the present invention, the concentration of the polypeptide used during polypeptide pre-incubation is 10 μg / mL.

[0014] The present invention also provides the use of the aforementioned polypeptide in the preparation of reagents for promoting the replication of porcine epidemic diarrhea virus.

[0015] Description of the invention principle:

[0016] Given that existing methods for isolating, propagating, and preparing attenuated vaccine candidate strains for PEDV virus have not yielded ideal results, this invention proposes a novel solution: designing a polypeptide to enhance PEDV replication capacity, thereby increasing viral replication efficiency.

[0017] During the research, the applicant noted that the nucleocapsid (N) protein in the PEDV structural proteins is highly conserved and forms a complex with genomic RNA, affecting viral RNA synthesis, packaging, and viral particle assembly. The PEDV N protein also prolongs the cellular DNA synthesis phase (S phase), induces endoplasmic reticulum stress, and inhibits type III IFN production. The N-terminal domain (NTD) of the PEDV N protein mediates RNA binding and is a key domain affecting N protein function. Furthermore, the arginine contained in the N protein is a basic amino acid involved in various biological processes and can provide a crucial nutrient required during viral infection.

[0018] Based on the aforementioned research findings on the properties of the N protein and arginine, the applicant's research team clarified the infection regulatory mechanism of PEDV and innovatively proposed using arginine, a specific target site in the PEDV N protein, as the regulatory center for PEDV replication, providing a new approach to solutions. In existing research, there is no clear record of utilizing the properties of nucleocapsid (N) proteins and arginine to regulate the PEDV replication process.

[0019] To this end, the applicant conducted in-depth research and complex screening of arginine residues in the N-terminal domain (NTD) region of the PEDV N protein, ultimately confirming that arginine residue position 58 (N-R58) of the nucleocapsid protein determines the replication ability of PEDV. Based on this, the applicant further proposed the following peptide design scheme:

[0020] (1) Based on the N-terminal sequence characteristics of the PEDV N protein, the design focuses on arginine as the central amino acid, with some amino acids retained before and after it. Since the purity, reactivity, and preparation difficulty of the polypeptide are limited by its length, approximately 30 amino acids are generally preferred. Therefore, in this application, except for the transmembrane peptide (11 amino acids), the target polypeptide is designed to be 20 amino acids long.

[0021] (2) After determining the amino acid sequence of the polypeptide, a transmembrane peptide sequence was inserted at the N-terminus to assist the polypeptide in entering the cell, and finally the polypeptide (named R58-WT) was synthesized.

[0022] Validation in a natural PEDV infection model showed that the R58-WT peptide obtained in this application can significantly enhance PEDV replication.

[0023] Compared with the prior art, the beneficial effects of the present invention are:

[0024] 1. This invention identifies key sites in the N-terminal region of the PEDV N protein that affect viral replication through in-depth research. Taking advantage of the high conservation of this site among different coronaviruses, it proposes to use it as a novel target for modulating the viral replication process.

[0025] 2. This invention further provides a transmembrane peptide targeting the replication stage of PEDV based on a new target. This peptide showed a significant promoting effect in the PEDV infection model verification experiments of IPEC-J2, Vero, and ST cells, and can perfectly solve the problems of weak virulence, poor cell adaptability, and difficulty in passage in the process of rescuing attenuated PEDV strains.

[0026] 3. This invention clarifies the important regulatory function of the conserved arginine residue at the N-terminus of the PEDV nucleocapsid protein during PEDV replication. Based on this, a membrane-penetrating peptide targeting this site was designed to promote viral replication. This invention further enriches the application of membrane-penetrating peptides in enhancing viral replication capacity and improving rescue efficiency, and further contributes to the preparation of viral vaccine candidate strains.

[0027] 4. This invention also provides new insights for researchers to gain a deeper understanding of the regulatory patterns of viral infection and to find new clues for prevention and control in other similar coronavirus research. Attached Figure Description

[0028] Figure 1 This is a description of the structure of the R58-WT polypeptide in this invention.

[0029] Figure 2 This is a description of the properties of the R58-WT polypeptide in this invention.

[0030] Figure 3 To analyze the effects of different concentrations of R58-WT peptide on the viability of IPEC-J2 cells.

[0031] Figure 4 Analysis of the effect of R58-WT peptide on PEDV replication.

[0032] Figure 5 To analyze the role of the R58-WT peptide in PEDV infection of other susceptible cells. Detailed Implementation

[0033] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments. However, they should not be construed as limiting the scope of protection of the present invention. The present invention is not limited to the following embodiments. The test methods not described in detail in the embodiments are all conventional methods in the art.

[0034] Example 1: R58-WT peptide promotes PEDV replication

[0035] 1) Synthesis of peptides containing the N-terminal arginine residue of the PEDV N-protein

[0036] The PEDV N protein sequence (GenBank: MK409659.1) was downloaded from the NCBI database. Arginine at position 58 (N-R58) of this nucleocapsid protein can affect the replication ability of PEDV. Based on the description in the invention principle section, the amino acids before and after arginine were designed: 20 amino acids, including this arginine site, were extracted and added to form the R58-WT polypeptide. The specific sequence of this polypeptide is shown in Table 1, where the underlined abbreviation R represents the target arginine.

[0037] The synthesis of the R58-WT peptide product was commissioned to Shanghai Hongtai Biotechnology Co., Ltd. The peptide was tested and found to have a molecular weight of 4218.82 and a purity of 93.99%. The peptide properties are detailed below. Figure 2 .

[0038] Table 1 Synthetic polypeptide sequences

[0039] Serial Number polypeptide name sequence SEQ ID NO:1 R58-WT YGRKKRRQRRRQIGYWNEQIRWRMRRGERIE SEQ ID NO:2 CCPs YGRKKRRQRRR

[0040] 2) R58-WT peptide is non-toxic to IPEC-J2 cells.

[0041] Porcine intestinal epithelial cell line (IPEC-J2 cells) was treated with R58-WT peptide at concentrations of 1, 5, 10, 20, and 50 μg / mL, with Mock and Blank wells used as controls. Cell viability was measured after 24 h. CCK-8 dye was added to the wells, and after incubation for 1 h, absorbance was measured at 450 nm to calculate cell viability. The results showed that the cell viability values ​​of different concentrations of R58-WT were similar to those of the Mock group, indicating that the peptide was non-toxic to IPEC-J2 cells. Figure 3 ).

[0042] 3) PEDV N-R58-WT peptide can act as a viral enhancer to promote PEDV replication.

[0043] IPEC-J2 cells were pre-incubated with R58-WT peptide at different concentrations (1, 5, 10, 20, and 50 μg / mL) for 1 h, followed by PEDV infection with PEDV (MOI=1). After 4 h, trypsin (4 μg / mL) was added, along with an equal amount of peptide as during pre-incubation. Cells were lysed after 24 h, and cellular RNA and protein were harvested. The transcriptional levels of PEDV ORF1 and PEDV N genes were detected using a probe method, and the protein levels of PEDV N and PEDV S1 were detected by Western blot.

[0044] The results showed that the PEDV N-R58-WT peptide significantly promoted the expression of PEDV N in a dose-dependent manner between 1 and 10 μg / mL. Figure 4 The transcriptional level of PEDV ORF1 peaked at a peptide dosage of 5 μg / mL and decreased significantly above 10 μg / mL. The protein level of PEDV S1 was highest at a peptide dosage of 10 μg / mL. Figure 4 ).

[0045] Example 2: Application of PEDV N-R58-WT peptide in other susceptible cells

[0046] The R58-WT peptide was added to the African green monkey kidney cell line (Vero cells) and the porcine testicular cell line (ST cells) at the appropriate concentration in Example 1. After pre-incubation for 1 h, the peptide and trypsin (4 μg / mL) were added after 4 h of PEDV infection. Cell proteins were harvested after 24 h, and the expression level of PEDV-N protein was detected by Western blot.

[0047] The results showed that in Vero cells, PEDV N protein levels increased in a dose-dependent manner after treatment with wild-type peptide (WT). Figure 5 In ST cells, different concentrations of wild-type polypeptide (WT) all promoted the expression of PEDV N protein. Figure 5 The results above are the same as in Example 1, confirming the promoting effect of PEDV N-R58-WT on viral replication.

[0048] Analysis and Conclusion:

[0049] Based on the results of Examples 1 and 2, it can be seen that the R58-WT peptide provided by this invention can significantly promote the PEDV replication process. Therefore, it can be further used as a promoter targeting the PEDV viral replication stage, thereby increasing the rescue of attenuated strains for virus isolation and passage. Furthermore, based on the non-toxic effects exhibited by this peptide on susceptible cells such as IPEC-J2, Vero, and ST, its application value as a universally applicable replication promoter is further verified.

[0050] Based on the results of multiple verifications by the applicant, it was confirmed that the peptide showed the best effect in promoting the replication process of PEDV virus when used at a concentration of 10 μg / mL.

[0051] The scope of protection of this invention is not limited to the specific embodiments described above; it should also be understood that the terminology used in the embodiments of this invention is for describing specific embodiments and not for limiting the scope of protection of this invention. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, based on the knowledge of those skilled in the art and the description of this invention, any prior art methods, equipment, and materials similar to or equivalent to those described, used, and materials in the embodiments of this invention can be used to implement this invention. Various modifications and variations can be made to this invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this invention should be included within the scope of protection of this invention.

Claims

1. A polypeptide for enhancing porcine epidemic diarrhea virus replication, characterized in that, This polypeptide is a transmembrane polypeptide that targets the replication phase of PEDV, with arginine at position 58 in the nucleocapsid N protein sequence of PEDV as the target site; the polypeptide is named R58-WT polypeptide, and its amino acid sequence is shown in SEQ ID NO:

1.

2. The method for promoting the expression of PEDV-N protein by using the polypeptide according to claim 1, characterized in that, The method involves pre-incubating IPEC-J2, Vero, or ST cells with the polypeptide, then adding the same amount of polypeptide as during pre-incubation after PEDV infection, lysing the cells, harvesting the samples, and detecting the expression of PEDV-N protein in the cells.

3. The method according to claim 2, characterized in that, When performing peptide pre-incubation, the concentration of the peptide used is 10 μg / mL.

4. The use of the polypeptide of claim 1 in the preparation of a reagent for promoting the replication of porcine epidemic diarrhea virus.

Citation Information

Patent Citations

  • Polypeptide for inhibiting replication of porcine epidemic diarrhea virus and application thereof

    CN119119304A